Medical/Pharmaceuticals

IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

* IMU's AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time. * Waters Biosciences' technologies, including BD FACSDiscover™ and BD Rhapsody™ Instruments, will be used with IMU's AI analy...

2026-06-24 20:00 6939

Tarek Samad appointed EVP, Head of Research & Development at Lundbeck

VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Team (ELT) effective 1 September 2026. Tarek Samad succeeds Johan ...

2026-06-24 18:19 8184

Yidu Tech's Gong Yingying at Summer Davos: Building Evidence Infrastructure to Expand Access to Innovative Medicines

DALIAN, China, June 24, 2026 /PRNewswire/ -- On June 23, at the 17th Annual Meeting of the New Champions (Summer Davos 2026) hosted by the World Economic Forum in Dalian, Gong Yingying, Founder and Chairlady of Yidu Tech, participated in the panel discussion "Faster Drugs, Better Access?". She sh...

2026-06-24 17:30 8508

World's First Solid Tumor CAR-T Approved: Jiahui International Cancer Center Provides Access for Patients Worldwide

SHANGHAI, June 24, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) welcomes the approval of Satri-cel (CT041, Kaileimei®), the world's first CAR-T cell therapy approved for the treatment of a solid tumor, marking a historic milestone in cancer care and opening new possibilities for...

2026-06-24 17:01 6061

Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026

* Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart * Eptinezumab data explore patient-centered outcomes in chronic migra...

2026-06-24 16:08 5640

Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules

SHANGHAI, June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Everest Medicines and Hainan He...

2026-06-24 15:07 8302

WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations

SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production camp...

2026-06-24 14:39 7499

Milliken Expands Innovation Capabilities with New Polymer Solutions Pilot Plant in Pune, India

Facility strengthens ability to accelerate development and scale advanced materialsolutions for global markets.  PUNE, India, June 24, 2026 /PRNewswire/ -- Milliken & Company has opened a new state of the art pilot plant facility in Pune, India, further strengthening its polymer solutions busine...

2026-06-24 14:24 6039

UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapy

SHANGHAI, June 23, 2026 /PRNewswire/ -- UniXell Biotechnology Co., Ltd. ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic induced pluripotent stem cell (iPSC)-derived therapy for Parkinson's disease. Pair...

2026-06-24 14:04 5546

Finetech Debuts Fully Automatic Liquid Capsule Filling Machine at CPhI China 2026 in Shanghai

System delivers filling volume accuracy within ±2–3%, output of 15,600 capsules per hour, and in-line rejection rates below 0.2%, addressing critical dosing consistency requirements for pharmaceutical and nutraceutical manufacturers SHANGHAI, June 24, 2026 /PRNewswire/ -- Finetech Pharmaceutical ...

2026-06-24 13:57 6871

Cynosure Lutronic Spotlighted Structural Skin Tightening Innovation at IMCAS Asia 2026 in Bangkok

SINGAPORE, June 24, 2026 /PRNewswire/ -- Global medical aesthetics leader  Cynosure Lutronic presented its latest non-invasive innovations at IMCAS Asia 2026 in Bangkok (19–21 June), featuring XERF™, a structural skin tightening treatment that focuses on comfort, safety, flexibility and no downtim...

2026-06-24 13:14 7586

Great Place To Work Reveals Southeast Asia's Best Workplaces™ in Healthcare & Biopharma

SINGAPORE, June 24, 2026 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, today announced the inaugural Southeast Asia's Best Workplaces™ in Healthcare & Biopharma 2026 list — a landmark recognition honouring 15 outstanding organizations that have set the benchmark...

2026-06-24 12:18 7051

Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026

SHENZHEN, China, June 24, 2026 /PRNewswire/ -- From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhib...

2026-06-24 11:53 4719

Abbisko Therapeutics Deepens R&D Collaboration with Lilly

SHANGHAI, June 23, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical co...

2026-06-24 09:00 5915

Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311

SHANGHAI, June 23, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) of China has cleared the clinical trial application for its innovative L...

2026-06-24 08:00 6835

Abu Dhabi Opens Strategic Life Sciences Corridor to California Through Biocom Partnership

ABU DHABI, UAE, June 24, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Biocom California, one of the world's largest life sciences associations representing more than 1,800 biotechnology, pharmaceutical and medical techno...

2026-06-24 07:11 6942

Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications

BEIJING, June 23, 2026 /PRNewswire/ -- On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement withNuvectis, a U.S. biotechnology company. Under the agreement, Haisco has granted Nuvectis the ...

2026-06-23 21:17 6140

Chenwei Medical Showcases Advanced ICU Ventilators, Anesthesia Workstations and Emergency Transport Ventilator Solutions at WHX Miami 2026

MIAMI, June 23, 2026 /PRNewswire/ -- Following its participation in the AMCI International Critical Care Congress in Colombia, Chenwei Medical presented its latest innovations in ICU ventilation, anesthesia systems and emergency respiratory care at WHX Miami 2026.

2026-06-23 21:12 6489

EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services

PROVIDENCE, R.I., June 23, 2026 /PRNewswire/ -- EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded space has more than doubled the company's laboratory footprint, expanding the ...

2026-06-23 21:12 4512

Ambulatory Surgical Centres Poised for Sustained Growth as Healthcare Delivery Continues to Shift Beyond the Hospital

Frost & Sullivan identifies significant opportunities across ambulatory surgery, digital health, and connected care markets LONDON, June 23, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis highlights ambulatory surgical centres (ASCs) as one of the most significant growth opportunities r...

2026-06-23 20:17 5342
1 ... 34353637383940 ... 644

Week's Top Stories